🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-521600-21-00
Authorised Phase I

A Phase 1/1b Open-Label Dose-Escalation and Dose-Optimization Study of Bcl-2 Inhibitor BGB 21447 in Patients With Mature B Cell Malignancies

2025-521600-21-00 · tracked via the Priya Life Science EU tracker
Sponsor
Beigene Ltd.
Sponsor type
Pharmaceutical company
Therapeutic area
Neoplasms
Decision date
29/09/2025
Enrollment target
18
Sites
France, Italy

Condition studied

mature B-Cell malignancies

Eligibility

Age group
65+ years, 18-64 years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-521600-21-00 on CTIS ↗ ← All trials in the EU